This work furthers the development of an effective drug delivery platform for the inner ear that uses the cochlear bone as a depot for prolonged neurotrophic stimulation of spiral ganglion neurons. Our method may bypass the pitfalls of systemic administration—increased risk of side effects and insufficient levels of drug delivery—and the dangers related to opening the cochlea.